Pfiz­er is ax­ing its neu­ro­sciences di­vi­sion, lay­ing off 300 and dis­card­ing new drugs

Pfiz­er is start­ing out 2018 by rip­ping up its ear­ly-, mid-stage and pre­clin­i­cal R&D op­er­a­tions fo­cused on neu­ro­sciences and lay­ing off hun­dreds of work­ers en­gaged in the de­vel­op­ment work.

In a state­ment, Pfiz­er $PFE says it is is ax­ing about 300 work­ers in Con­necti­cut and Mass­a­chu­setts — about 100 each in An­dover, Gro­ton and Cam­bridgewhere it’s been con­cen­trat­ing its R&D ef­forts — and dis­card­ing a slate of Phase I/II and pre­clin­i­cal stud­ies.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.